Rgenta Therapeutics Secures $20 Million Seed Funding to Advance Targeted RNA Drug Development

VCBeat (WeChat ID: vcbeat) has learned that Rgenta Therapeutics (“Rgenta”) recently completed a $20 million seed financing round. The round was co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China, with participation from Cathay Capital and Legend Star.Rgenta has built a unique platform for the discovery and screening of RNA-related targets, dedicated to developing targeted RNA therapeutics against disease-associated targets to address unmet clinical needs.

Currently, the company has multiple projects advancing through preclinical research, with indications in areas of unmet clinical need such as oncology and rare diseases.

Rgenta’s distinguished founding team comprises world-class computational biologists, genomics experts, and medicinal chemists, all possessing extensive experience in both scientific research and industry.

Dr. Hua Lin Xi, the founder, possesses nearly two decades of R&D and management experience at major international pharmaceutical companies and currently serves as the full-time CEO of Rgenta. Dr. Xi holds a Ph.D. in Bioinformatics from Boston University and has extensive R&D experience in computational biology and genomics across both industry and academia. He has previously served as an Associate Professor at the University of Massachusetts Medical School, a Visiting Professor at Brandeis University, Senior Principal Scientist, Research Fellow, and Group Leader at Pfizer, and Head of Computational Biology and Genomics at AbbVie. He has comprehensively engaged in all stages of preclinical drug development, including target validation and drug discovery. The projects he has led and overseen have covered areas such as oncology and neuroscience, demonstrating his rich experience in team management and leadership. Additionally, Dr. Xi serves as the Principal Investigator (PI) for the GTEx Genomics Project.

Dr. Zhiping Weng, Co-Founder, is a Tenured Professor at the University of Massachusetts Medical School. Professor Weng has achieved remarkable scientific accomplishments in the fields of computational biology, genomics, epigenomics, and RNA regulation. Furthermore, Professor Weng co-leads the Data Analysis Centers for two international genome projects, ENCODE and psychENCODE.

Co-founder Dr. Travis Wager brings over 20 years of drug development experience at Pfizer, with extensive expertise in rare diseases, cardiovascular and cerebrovascular disorders, and neurological conditions. He has successfully advanced eight drug molecules into clinical trials. Dr. Wager also has startup experience, having served as Vice President at Aquinnah Pharmaceuticals, and currently serves as the full-time Chief Scientific Officer (CSO) of Rgenta.

In addition to its strong founding team, the company has also established a distinguished Scientific Advisory Board in the fields of genomics and RNA biology. The board includes Dr. Phillip Zamore, Chair of the RNA Therapeutics Institute and Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, as well as co-founder of two biotechnology companies, Alnylam Pharmaceuticals and Voyager Therapeutics; Dr. Charles DeLisi, Metcalf Professor of Science and Engineering at Boston University, a visionary change agent hailed as the father of the Human Genome Project; and Dr. Friedrich Metzger, CEO of Versameb and former Head of Rare Diseases at Roche, who led the development of risdiplam, a small-molecule RNA splicing modifier for the treatment of spinal muscular atrophy.

Bringing together a world-class team, Rgenta aims to develop RNA-targeted therapeutics for targets that are highly relevant to disease but have been undruggable through traditional approaches.

For small-molecule therapies, the vast majority of their targets are proteins. The human genome expresses and translates approximately 20,000 proteins, among which disease-related proteins account for about 10%–15% (2,000–3,000). However, among currently approved drugs, fewer than 700 protein targets have been utilized. Many proteins lack “druggability,” meaning it is difficult to develop inhibitory small molecules against them. These targets currently lack effective intervention strategies but hold substantial development value and potential. Furthermore, only about 1.5% of the human genome is transcribed into protein-coding RNA, while approximately 70% is transcribed into non-coding RNA. Drug development targeting RNA can regulate gene expression and offers significant potential and opportunities.

Rgenta is dedicated to developing drugs for targets traditionally considered “undruggable.” These target genes are often located in key regulatory programs and signaling pathways of disease progression, making them ideal candidates for therapeutic intervention. To this end, Rgenta has built a unique technology platform for RNA-related target discovery and compound screening. This platform leverages extensive genomic data and advanced algorithms to identify RNA targets that can be selectively modulated by small molecules, and employs efficient targeted RNA assays to rapidly screen and optimize functional lead compounds. By regulating RNA function with small-molecule drugs, Rgenta aims to overcome the challenge of targeting proteins traditionally deemed “undruggable.”

Dr. Hua Lin Xi, Founder and CEO of the Company, stated, “We are delighted to have completed this seed financing round in partnership with a specialized fund in the biopharmaceutical sector. With their support, we can rapidly advance our existing RNA-targeting programs into preclinical studies. Looking ahead, we will identify more high-value RNA targets across diverse therapeutic areas, further enriching our pipeline. By modulating RNA function, we aim to address many of the treatment challenges associated with conventional approaches and alleviate the suffering of patients.”

Travis Wager, Ph.D., Co-Founder and Chief Scientific Officer (CSO) of Rgenta, stated, “Rgenta’s RNA-targeting platform offers an innovative approach that enables us to engage previously undruggable targets with high disease relevance. The key to our platform’s success lies in our ability to analyze large-scale genomics data and identify regulatory sites within RNA that can be effectively and selectively modulated by small molecules. Our proprietary technology platform facilitates the rapid screening of drug-like small molecules against diverse RNA targets, thereby regulating protein production or altering protein function.”